Stockreport

Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia

Onconova Therapeutics, Inc.  (ONTX) 
Last onconova therapeutics, inc. earnings: 11/12 05:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.onconova.com/investor-overview
PDF Rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood countsPatients with response or stable disease had one year longer survival than non-re [Read more]